Logo image
A Second Chance for a PPAR gamma Targeted Therapy?
Journal article   Open access   Peer reviewed

A Second Chance for a PPAR gamma Targeted Therapy?

Andrew W. Norris and Curt D. Sigmund
Circulation research, Vol.110(1), pp.8-11
01/06/2012
DOI: 10.1161/RES.0b013e3182435d88
PMCID: PMC3583552
PMID: 22223206
url
https://doi.org/10.1161/RES.0b013e3182435d88View
Published (Version of record) Open Access

Abstract

A new class of non-agonist ligands target the transcription factor PPAR gamma and promote expression of insulin-sensitizing adipokines. They have potent antidiabetic actions, yet they lack several of the adverse effects commonly associated with thiazolidinediones. The ligands may represent a new class of anti-diabetes medications that preserve the most beneficial effects of PPAR gamma activation without imparting major side effects, which have limited the clinical usefulness of thiazolidinediones.
Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Hematology Life Sciences & Biomedicine Peripheral Vascular Disease Science & Technology

Details

Metrics

Logo image